Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Iván O. Rosas; Norbert Bräu; Michael R. Waters; Ronaldo C. Go; Bradley D. Hunter; Sanjay Bhagani; Daniel J. Skiest; Mariam Aziz; Nichola Cooper; Ivor S. Douglas; Sinisa Savic; Taryn Youngstein; Lorenzo Del Sorbo; Antonio Cubillo Gracián; David J. De La Zerda; Andrew Ustianowski; Min Bao; Sophie Dimonaco; Emily Graham; Balpreet Matharu; Helen Spotswood; Larry Tsai; Atul Malhotra

doi:10.1056/nejmoa2028700

Abstract

In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F. Hoffmann-La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number, NCT04320615.).

Keywords

TocilizumabMedicinePlaceboInternal medicinePneumoniaConfidence intervalPopulationOdds ratioRandomized controlled trialDisease

Affiliated Institutions

Related Publications

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama , Jian Han , Linda Yau +17 more

In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mec...

2020 New England Journal of Medicine 1297 citations

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin , Paolo A. Ascierto , Brigitte Dréno +16 more

The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, ...

2014 New England Journal of Medicine 1969 citations

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone , Matthew J. Frigault , Naomi Serling‐Boyd +45 more

Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, becaus...

2020 New England Journal of Medicine 1404 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby , Marion Mafham , Louise Linsell +26 more

BACKGROUND: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrol...

2020 New England Journal of Medicine 1266 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 16
Pages: 1503-1516
Citations: 1065
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1065

OpenAlex

Cite This

APA Style

                            
                                
                                    Iván O. Rosas, 
                                
                                    Norbert Bräu, 
                                
                                    Michael R. Waters
                                
                                et al.
                            
                            (2021). 
                            Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. 
                            New England Journal of Medicine
                            , 384
                            (16)
                            , 1503-1516.
                            https://doi.org/10.1056/nejmoa2028700
                        

Identifiers

DOI: 10.1056/nejmoa2028700